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Background: Quantitative measurement of HIV-1 RNA levels in plasma (‘viral load’) plays a central role in
clinical management. The choice of assay platform can inﬂuence results and treatment decisions.
Objective: To compare the analytical performance of the new TMA-based Hologic Aptima® HIV-1 Quant
Dx assay with that of three PCR-based assays: Abbott RealTime HIV-1, Qiagen Artus® HI Virus-1 QS-RGQ,
and Roche CAP/CTM HIV-1 Test v2.
Study design: Assay performance was evaluated using Acrometrix HIV-1 RNA Standard panels; the 3rd
WHO HIV-1 RNA International Standard (12–500 copies/ml; 6 dilutions; 9 replicates); and plasma sam-
ples from 191 HIV-positive patients.
Results: Aptima showed high (>0.99) precision, accuracy and concordance with the Acrometrix Stan-
dards across a wide dynamic range (2.0–6.7 log10 copies/ml). Variance caused up to 2.1 (Aptima), 1.7
(RealTime), 7.5 (Artus), and 1.9 (CAP/CTM) fold changes in the International Standard quantiﬁcations
at 50–500 copies/ml. HIV-1 RNA detection rates in plasma samples were 141/191 (74%), 119/191 (62%),
108/191 (57%), and 145/191 (76%) for Aptima, RealTime, Artus and CAP/CTM, respectively. For categoris-
ing samples either side of 50 copies/ml, Aptima had excellent agreement with RealTime (kappa 0.92; 95%
CI 0.87–0.98); lowest agreement was with Artus (kappa 0.79; 95%CI 0.70–0.88). Aptima quantiﬁcations
weremean0.12 and0.06 log10 copies/ml higher comparedwith RealTime andCAP/CTM, respectively, and
0.05 log10 copies/ml lower compared with Artus. Limits of agreement were narrowest when comparing
Aptima to RealTime.
Conclusions: The new Aptima HIV assay is sensitive, precise, and accurate. HIV assays exhibit discordance
at low HIV-1 RNA copy numbers.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
HIV-1RNAquantitation (viral load) is used tomonitor treatment
efﬁcacy, helping clinicians make decisions regarding switching
or continuing the current antiretroviral therapy (ART). According
to HIV treatment guidelines, ART is considered effective when it
leads to undetectable HIV-1 RNA in plasma, whereas results above
50 copies/ml may trigger further investigations [1–5]. Because
Abbreviations: AS, Acromterix HIV-1 standards; CV, coefﬁcient of variation; IS,
3rd WHO HIV-1 International Standard; LLOQ, lower limit of quantitation; LTR, long
terminal repeat; TMA, transcription mediated ampliﬁcation.
∗ Corresponding author at: Infection and Immunity, Royal Liverpool University
Hospital, Liverpool L7 8XP, United Kingdom. Tel.: +44 151 706 4405.
E-mail address: mark.hopkins@rlbuht.nhs.uk (M. Hopkins).
this threshold is close to the lower limit of quantitation (LLOQ)
of most commercially available assays (20–75 copies/ml), assay
performance at low HIV-1 RNA levels can signiﬁcantly inﬂuence
management decisions during ART.
In the UK, nucleic acid ampliﬁcation tests are standard practice
for monitoring of HIV infection [1–4,6]. These assays are largely
based on real-time PCR and share similar performance character-
istics [7–11]. Recently the Hologic Aptima HIV-1 Quant Dx assay
(AptimaHIV) becamecommercially available in theUK.AptimaHIV
is based on real-time transcription mediated ampliﬁcation (TMA),
a technology with high sensitivity for detection of pathogen RNA
[12,13].
While PCR-based assays have been evaluated side-by-side in
many studies [10,14,15], theperformanceofAptimaHIVhasnot yet
been compared with that of other assays. UK clinical laboratories
http://dx.doi.org/10.1016/j.jcv.2015.05.020
1386-6532/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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are required to validate assay performance prior to implementing
any new test in to routine diagnostic use [16].
2. Objectives
The aimof this studywas to compare the analytical performance
of Aptima HIV with that of three PCR-based assays: Abbott Real-
Time HIV-1 (RealTime), Qiagen artus® HI Virus-1 QS-RGQ (Artus),
and Roche COBAS® AmpliPrep/COBAS® Taqman HIV-1 Test v2
(CAP/CTM), with a particular focus on samples with low HIV-1 RNA
copy number.
3. Study design
3.1. Viral load assays
All HIV-1 RNA assays were performed according to the manu-
facturer’s instructions.
3.1.1. Aptima HIV
Plasma (0.75ml) was transferred into a sample aliquot tube,
vortexed and centrifuged at 1000× g for 10min prior to load-
ing onto the Panther system which extracted HIV-1 RNA from
0.5ml of plasma using automated target capture technology, fol-
lowed by ampliﬁcation and detection of HIV-1 long terminal repeat
(LTR) and pol gene targets (Hologic Inc., San Diego, CA, USA). The
reported LLOQ is 30 copies/ml with an upper limit of quantitation
of 107 copies/ml [17].
3.1.2. RealTime
Plasma (1ml)wasaliquoted, vortexedandcentrifugedat431× g
for 5min prior to loading into the Abbott m2000 sample prepa-
ration system which extracted HIV-1 RNA from 0.6ml of plasma,
followedbyampliﬁcation anddetectionof theHIV-1 integrase gene
on the Abbottm2000rt PCR instrument (AbbottMolecular, Inc., Des
Plaines, IL, USA). The LLOQ is 40 copies/ml and the upper range of
quantitation is 107 copies/ml [18].
3.1.3. Artus
RNA was extracted from 1.0ml of plasma using the Qiagen
QIAsymphony SP automated extractor followed by ampliﬁca-
tion and detection of HIV-1 LTR on the Qiagen Rotor-Gene Q
real-time PCR instrument (Qiagen GmbH, Hilden, Germany). The
LLOQ is 45 copies/ml and the upper range of quantitation is
4.5×107 copies/ml [19].
3.1.4. CAP/CTM v2
Plasma (1.0ml) was transferred into an input S-tube and loaded
onto the Cobas Ampliprep instrument where RNA was extracted
from0.85ml of sample prior to automated ampliﬁcation anddetec-
tion of HIV-1 LTR and gag targets on the COBAS® Taqman Analyser
(Roche Molecular Systems, Inc., Pleasanton, CA, USA). The LLOQ is
20 copies/ml and the upper range of quantitation is 107 copies/ml
[20].
3.2. Evaluation of Acrometrix Standards (AS)
Linearity and accuracy of all four systems was assessed
by analysing panels of AS (Acrometrix HIV-1 panel
copies/ml, Life Technologies, Carlsbad, CA, USA) in the range
2.00–6.70 log10 copies/ml. Aptima HIV was further evaluated with
triplicate samples constructed from an AS panel diluted 1:3 using
Basematrix HIV-1 negative human plasma (SeraCare, Lifescience,
US). Linear regression analysis was performed and concordance
correlation coefﬁcient calculated.
3.3. Evaluation of 3rd WHO International HIV-1 RNA Standards
(IS)
Low-level precision of each assay was compared using IS
(National Institute for Biological Standards and Control, UK) con-
taining 185,000 IU/ml of HIV-1 subtype B. Nine replicates of 6 IS
dilutions in Basematrix were independently extracted and tested
on all four systems over three days. The dilutions contained 28, 56,
112, 224, 558 and 1116 IU/ml HIV-1, corresponding to 12.5, 25, 50,
100, 250 and 500 copies/ml, respectively (when using the Qiagen
conversion factor of 1 IU/ml =0.45 copies/ml). Coefﬁcients of vari-
ation were calculated at dilution points above the highest LLOQ
across the 4 assays (>45 copies/ml).
3.4. Evaluation of assay performance with external quality
assurance (EQA) panels
A panel of 8 samples was commissioned in quadruplicate from
Qnostics (Glasgow, UK) and analysed by all four HIV assays. The
panel contained dilution series of subtypes B and C and a single
A/G sample.
3.5. Evaluation of assay performance with clinical samples
3.5.1. Clinical samples
A total of 191 surplus plasma samples from HIV-positive
patients attending for care at the Royal Liverpool University Hos-
pital, UK between January and December 2013 were used in this
evaluation. Samples were excluded from analysis if less than 5ml
of plasma was available. Plasma was separated within 4–6h of
collection and stored at −80 ◦C in four separate aliquots with a sin-
gle freeze–thaw cycle prior to analysis on the four systems. HIV
subtype was noted when available from routine HIV genotypic
resistance reports. Thesubtypewasassigned fromprotease (codons
1–99) and reverse transcriptase (codons 1–235) sequences using
HIVdb program from Stanford University. HIV subtype was B for
45 patients, non-B for 44 patients (A/B= 1, A/C=1, A/CRF01 AE=1,
C =21, CRF01 AE=7, CRF02 AG=6, CRF02-AG/B=1, D/A=2, G=2,
H=1, K/F =1), and unknown for 102 patients.
3.5.2. Pair-wise comparison of assay performance
Agreement for HIV-1 RNA detection and for categorisation
above or below the 50 copies/ml threshold was assessed by calcu-
lating the kappa value for each pair-wise comparison. Regression
and Bland–Altman analysiswere performed on quantitative results
and differences were tested using paired t-tests. All analyses
were conducted using Microsoft Excel 2010 and MedCalc software
v13.3.0.
4. Results
4.1. Accuracy and linearity of assays across the dynamic range
All Aptima HIV measurements were within 0.24 log10 copies/ml
of the Acrometrix target value and data were linear across
the dynamic range (precision=0.9977; accuracy =0.9972; concor-
dance=0.9949). Results from all four assays were highly correlated
(linear regression analysis; R2 >0.99) (Fig. 1).
4.2. Precision of HIV-1 RNA quantitation using low-level WHO
International Standard (IS)
Aptima HIV detected HIV-1 RNA in 8/9 and 9/9 replicates with
nominal values 12 and 25 copies/ml, respectively. Quantitative
results were reported for 27% Aptima HIV, 33% RealTime, 38% Artus
and 28% of CAP/CTM replicates at these two low-level dilution
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Fig. 1. Viral load measurements with Aptima HIV (square), RealTime (cross), Artus (triangle) and CAP/CTM (circle) for the Acrometrix standard panel ranging from 2.00 to
6.70 log10 copies/ml. The Pearson’s correlation coefﬁcient (R2) = 0.9993, 0.9960, 0.9969 and 0.9966 for Aptima HIV, RealTime, Artus and CAP/CTM, respectively.
points. Analysis of replicates in the range50–500 copies/ml showed
precision decreased close to the LLOQ in all assays (Table 1). Aptima
HIV coefﬁcient of variation (CV) values were 18–44% for replicates
in the range 250–50 copies/ml, although the lowest CV were seen
at 500 copies/ml with RealTime (8%) and CAP/CTM (9%). The corre-
sponding value for Aptima HIV was 17% which related to a 1.3 fold
change in 95% CI and this increased to 2.1 at 50 copies/ml. Equiv-
alent CV values using log transformed data of the four IS dilutions
(1.7, 2.0, 2.4 and 2.7 log10 copies/ml) were in the range of 2.7–9.1%,
1.3–5.2%, 4.5–15.1% and 1.4–10.2% log copies/ml for Aptima HIV,
RealTime, Artus and CAP/CTM.
Table 1
Detection and quantiﬁcation of replicates (n=9) of 3rd WHO HIV-1 RNA international standard diluted to nominal low-level copies/ml.
Aptima HIV RealTime Artus CAP/CTM
50copies/ml Quantiﬁed/detected (n) 8/9 8/9 7/9 9/9
Mean (copies/ml) 62 75 109 64
CV (%) 44 22 83 41
SD 27 16 90 26
95% CI 40–85 63–88 26–193 44–84
Fold change 95% CI 2.1 1.4 7.5 1.9
100 copies/ml Quantiﬁed/detected (n) 9/9 9/9 9/9 9/9
Mean (copies/ml) 122 137 214 138
CV (%) 20 34 32 22
SD (copies/ml) 24 46 68 30
95% CI 104–141 102–173 162–266 115–161
Fold change 95% CI 1.4 1.7 1.6 1.4
250 copies/ml Quantiﬁed/detected (n) 9/9 9/9 9/9 9/9
Mean (copies/ml) 353 311 346 295
CV (%) 18 13 32 19
SD (copies/ml) 64 41 112 55
95% CI 304–402 279–343 260–432 253–338
Fold change 95% CI 1.3 1.2 1.7 1.3
500 copies/ml Quantiﬁed/detected (n) 9/9 9/9 9/9 9/9
Mean (copies/ml) 615 573 735 589
CV (%) 17 8 26 9
SD (copies/ml) 102 47 194 51
95% CI 536–693 537–609 585–884 549–628
Fold change 95% CI 1.3 1.1 1.5 1.1
Mean, 95% conﬁdence intervals (CI), standard deviation (SD), coefﬁcient of variation (CV) calculated only at the four dilutions with nominal values above the LLoQ of all
assays.
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4.3. External quality assessment panels
Aptima HIV was fully concordant with expected EQA results
(Table 2). Quantitation of the subtype B dilutions was reproducible
using the Aptima HIV assay. Quantitation of subtype C samples
varied between assays by up to 0.76 log10 copies/ml.
4.4. Comparison of assay sensitivity with clinical samples
A total of 191 samples from HIV-infected patients were ana-
lysed. Aptima HIV detected HIV-1 RNA in 74% samples, similar
to the proportion reported positive by CAP/CTM (Table 3). When
categorising clinical samples above or below the 50 copies/ml
threshold, 59%, 59%, 56% and 55% were quantiﬁed as <50 copies/ml
by Aptima HIV, RealTime, Artus and CAP/CTM, respectively
(Table 4). Here, Aptima HIV agreement was highest with
RealTime (kappa=0.924). Further analysis within the range
(50–500 copies/ml) demonstrated that 20 (11%), 19 (10%), 25 (13%)
and 30 (16%) were quantitated by Aptima HIV, RealTime, Artus
and CAP/CTM, respectively. Within these thresholds, Aptima HIV
agreement was highest with RealTime (95%, kappa=0.743) and
lowest with CAP/CTM (88%, kappa=0.497). The number of samples
reported between 50 and 200 copies/ml was 16 (8%) Aptima HIV,
17 (9%) RealTime, 18 (9%) Artus and 22 (12%) CAP/CTM. Categori-
sation of clinical samples at the 200 copies/ml threshold is shown
in Supplementary data.
4.5. Analysis of discordant clinical samples
All assays gave at least one discordant result. The four assays
had agreement in quantiﬁcation above 50 copies/ml for 67/191
(35.1%) samples. Aptima HIV, RealTime, Artus and CAP/CTM dis-
crepantly reported 3, 1, 4 and 4 samples as <50 copies/ml when
the other three assays gave values above this cutoff. Conversely,
the number of samples reported ≥50 copies/ml by only one
assay when corresponding results from the other three platforms
were all below this threshold were 1 (66 copies/ml), 0, 6 (range
63–166 copies/ml) and 6 (range 55–131 copies/ml) for Aptima HIV,
RealTime, Artus and CAP/CTM, respectively. At the 200 copies/ml
threshold, 1 (507 copies/ml), 0, 5 (range 241–520 copies/ml) and 3
(range 250–419 copies/ml) discordant samples were identiﬁed for
Aptima HIV, RealTime, Artus and CAP/CTM, respectively, when the
other three assays reported below this value.
4.6. Quantitative correlation between Aptima HIV and the PCR
assays
Linear regression analysis for all clinical results >LLOQ (n=87
for Aptima HIV, 84 for RealTime, 86 for Artus and 107 for CAP/CTM)
showed good correlation between Aptima HIV and the three PCR
assays (R2 >0.93) (Supplementary data). AptimaHIVquantiﬁed sig-
niﬁcantly higher than RealTime (P=0.001) with a mean bias of
0.12 log10 copies/ml (Fig. 2A). Overall, >93% of the paired Aptima
HIV results fell within the 95% CI levels of agreement when com-
pared with the PCR assays by Bland–Altman analysis, and limits of
agreement were narrowest between Aptima HIV and RealTime at
0.49 log copies/ml either side of the mean. There were 5 discrepant
samples outside the 95%CI level of agreement between Aptima HIV
and RealTime (2 subtypes B, 2 C and 1 A/B), 5 between Aptima HIV
and Artus (1 subtype B, 1 C, 1 D/A, 1 CRF01 AE and 1 unknown),
and 3 between Aptima HIV and CAP/CTM (2 subtypes C and 1
CRF02 AG). Of these 11 discrepant samples, 5 had low copy num-
bers (<3 log10 copies/ml) and at least 3 were due to an unexpected
result by another assay (Table 5).
Comparison of RealTime or CAP/CTM to Artus also revealed 5
discrepant samples between each PCR assay compared (Table 5).
Artus quantitation was signiﬁcantly higher on average than Real-
Time (P=0.0001) and CAP/CTM (P=0.002). Mean differences for
RealTime minus Artus, RealTime minus CAP/CTM and CAP/CTM
minus Artus were −0.17, −0.05 and −0.14 log copies/ml, respec-
tively (Fig. 2B).
5. Discussion
HIV-1 plasma viral load is a routine investigation for monitor-
ing of HIV-1 infected individuals. In a recent report, 77% (58/75) of
laboratories reported using commercial real-time PCR assays [21].
Two of the principal real-time assays, Abbott RealTime and Roche
CAP/CTM v2, are both FDA-approved and their performance is well
documented in the literature [15,22–29]. Characteristics of theQia-
genArtusHIV-1 real-timePCR test launched in 2010on theQS-RGQ
system have also been described [10,30].
The Aptima HIV-1 Quant Dx assay on the Panther system was
approved for European use in the diagnosis and monitoring of HIV-
1 infection in November 2014. It is the ﬁrst commercially available
real-time, TMA assay for quantitation of viral RNA levels and the
evaluation presented here demonstrated Aptima HIV results are
highly correlatedwith thoseobtained fromreal-timePCR technolo-
gies. The Aptima HIV test was highly accurate for quantitation of
HIV-1 subtype B in the standard panels. Results were similar to
those reported by Manak et al. where Aptima HIV quantiﬁcation
was comparable to RealTime and CAP/CTM for all major group M
HIV-1 subtypes and four group O isolates [31].
Linearity can be affected by poor precision and this may be
more evident close to the LLOQ of an assay. Overall, Aptima HIV
quantitation of IS did not exceed 20% CV, except at 50 copies/ml
where variation could represent up to two-fold change in viral load.
Below 500copies/ml, imprecision was observed with all assays but
only Artus HIV was signiﬁcantly less reliable. This is similar to the
pattern described previously where Artus HIV had lower repro-
ducibility than RealTime and CAP/CTM [15,32]. Whilst a higher
number of replicates is needed to give a deﬁnitive calculation of
total imprecision for each platform, the wide limits of agreement
observed in Bland–Altman analysis of Artus measurements sup-
ports the greater likelihood of analytical variation using this test
[33]. Mean quantitation of clinical samples was similar across all
assayswith observed bias <0.17 log10 copies/ml. However, it would
be prudent not to switch assays interchangeably during patient
monitoring where this can be avoided.
DHHS refer to optimal suppression below the assay limit of
detection, with virological failure as the inability to achieve or
maintain HIV-1 RNA load below 200copies/ml [3]. Both BHIVA
and EACS utilise a threshold of 50 copies/ml to deﬁne suppres-
sion [1,5]. Here virological failure is deﬁned as inability to achieve
<50 copies/ml after 6months of starting ART, or conﬁrmed rebound
>400 copies/ml after suppression below 50copies/ml. A single blip
between 50 and 400 copies/ml is not a cause for clinical concern if
preceded and followed by viral loads below 50copies/ml. Thus low
level HIV-1 RNA quantitation impact on patient management.
Whilst inter-assay correlation was high overall, concordance
was reduced closer to the lower limits of assay performance. This
was emphasised with considerable disagreement between tests to
designate complete viral suppression to undetectable levels: HIV-1
RNA was detected by at least one assay in 162/191 (85%) samples
whereas the four assays agreed HIV-1 RNA was present in only 92
(48%). Hologic states a lower limit of detection of 13 copies/ml (IS)
for the Aptima HIV assay and data presented here conﬁrms the
test is highly sensitive with clinical samples. Use of ultra-sensitive
assays has demonstrated the presence of very low-level HIV-1
replication even in the presence of intensive therapy and the clini-
cal signiﬁcance of these ﬁndings has been reviewed elsewhere [34].
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Table 2
Summary of Qnostics HIV-1 RNA assay evaluation panel results from Aptima HIV, Abbott RealTime, Qiagen Artus and Roche CAP/CTM assays.
Quantitative result (Log copies/ml) Log difference
Sample HIV subtype Expected Aptima RealTime Artus CAP/CTM Aptima–expected Aptima–RealTime Aptima–Artus Aptima–CAP/CTM
Qn1 A/G 4.5 4.79 4.73 4.72 4.47 0.29 0.06 0.07 0.32
Qn2 Neg ND ND ND ND ND
Qn3 C 4 4.25 3.86 3.49 3.97 0.25 0.39 0.76 0.29
Qn4 C 3 2.86 3.00 2.45 2.97 −0.14 −0.14 0.41 −0.12
Qn5 B 3.5 3.35 3.60 3.52 3.25 −0.15 −0.25 −0.17 0.11
Qn6 B 3.5 3.28 3.54 3.60 3.35 −0.22 −0.26 −0.32 −0.07
Qn7 B 3.1 3.05 3.21 3.27 2.91 −0.05 −0.17 −0.22 0.14
Qn8 B 2.4 2.39 2.20 2.37 2.26 −0.01 0.19 0.19 0.14
Mean 0.00 −0.02 0.07 0.10
Table 3
Comparison between Aptima HIV and the other assays for detection of HIV-1 RNA in clinical samples.
RealTime Artus CAP/CTM
Detected Not detected Detected Not detected Detected Not detected Total
Aptima HIV
Detected 113 28b 100 41d 130 11f 141 (73.8%)
Not Detected 6a 44 8c 42 15e 35 50 (26.2%)
Total 119 (62.3%) 72 (37.7%) 108 (56.5%) 83 (43.5%) 145 (75.9%) 46 (24.1%) 191
Kappa 0.597 0.453 0.638
Standard error 0.060 0.0622 0.0646
95% CI 0.479–0.714 0.331–0.575 0.512–0.765
a Discordant results were in the range: <40 copies/ml.
b Discordant results were in the range: <30 copies/ml.
c Discordant results were in the range: <45 copies/ml.
d Discordant results were in the range: <30–507 copies/ml.
e Discordant results were in the range: <20–25 copies/ml.
f Discordant results were in the range: <30 copies/ml.
Table 4
Comparison between Aptima HIV and the other assays for quantitation of samples < and ≥50 copies/ml.
RealTime Artus CAP/CTM
≥50 <50 ≥50 <50 ≥50 <50 Total
Aptima HIV
≥50 75 4b 72 7d 74 5f 79 (41.4%)
<50 3a 109 13c 99 13e 99 112 (58.6%)
Total 78 (40.8%) 113 (59.2%) 85 (44.5%) 106 (55.5%) 87 (45.5%) 104 (54.5%) 191
Kappa 0.924 0.787 0.809
Standard error 0.0281 0.0451 0.0428
95% CI 0.869–0.979 0.698–0.875 0.725–0.892
Individual assay results for these samples are given in Supplementary data.
a Discordant results were in the range: 57–90 copies/ml.
b Discordant results were in the range: 50–77 copies/ml.
c Discordant results were in the range: 55–166 copies/ml.
d Discordant results were in the range: 50–507 copies/ml.
e Discordant results were in the range: 55–419 copies/ml.
f Discordant results were in the range: 66–175 copies/ml.
As such, discrepancies in low-level RNA detection may not repre-
sent viral escapebut could be attributed to randomvariationwithin
the conﬁdence intervals at the limit of detection in each assay
[32,35]. Hence, quantitative values in the region 50–400 copies/ml
are often investigated further in UK clinical practice with a follow-
up sample requested to conﬁrmviraemia [1]. AptimaHIV identiﬁed
fewer discordant samples above 50 copies/ml compared to Artus
and CAP/CTM. This has potential implications for clinical practice
given that fewer patients would be recalled unnecessarily to inves-
tigate blips and low-level viraemia.
Similar to previous comparison studies testing multiple sub-
types, discrepant samples identiﬁed by Bland–Altman analysis
included those with lower viral loads and non-B subtypes
[7–11,36]. There may be issues relating to detection of low level
viraemiawith speciﬁc assays. Previous investigators reported tran-
sition to the CAP/CTM v2.0 assay was followed by an increase of
quantiﬁable viral loads in patients with prior viral suppression,
which were then below the limit of detection in subsequent viral
load measurements [29]. Similar to CAP/CTM v2.0, Aptima HIV is
a highly sensitive dual-target assay. However, Aptima technology
differs in that TMA inherently targets RNA molecules for ampliﬁ-
cation. This reduces the likelihood of proviral DNA ampliﬁcation
contributing to low-level quantitative signals. Likewise, preferen-
tial recovery of RNA over DNA has been proposed for the RealTime
HIVprotocol [37]. These technological factorsmayaccount for some
of the variation observed between assays at low viral loads.
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Fig. 2. (A) Comparison of Aptima HIV and each PCR assay by Bland–Altman analysis for samples quantitated above the LLOQ of the assays. (B) Inter-PCR comparison by
Bland–Altman analysis for samples quantitated above the LLOQ of the assays. The solid horizontal lines represent the mean differences between the values; the horizontal
dotted lines represent the mean differences ±1.96 SD (representing the 95% conﬁdence limits of the agreement) and the values below the dotted lines are the log10 copies/ml
values corresponding to the mean±1.96 SD. There were 5 discrepant samples outside the 95% CI level of agreement between Aptima HIV and RealTime (2 subtypes B, 2C
and 1 A/B), 5 between Aptima HIV and Artus (1 subtype B, 1C, 1 D/A, 1CRF01 AE and 1 unknown) and 3 between Aptima HIV and CAP/CTM (2 subtypes C and 1CRF02 AG).
Variation at low-copy number highlights the importance of
selecting an assay with precision across the dynamic range, and
of consecutive testing to conﬁrm increases in HIV-1 RNA load. The
relationship between variability of low viraemia levels and treat-
ment efﬁcacy is an area of active debate and controlled clinical
studies are needed to further understand the signiﬁcance of blips
for patientmanagement [34]. It is vital that dialogue exists between
clinic and laboratory to understand and interpret low copy number
results. This evidence is needed to guide consensus opinion.
The strength of this study is the use of three commercial
comparator PCR assays with Aptima HIV. This allowed direct
comparison between the different commercial platforms, easier
identiﬁcation of outlier results in clinical samples and showed that
discrepancies can occur with all assays, particularly at low copy
Table 5
Summary of individual quantitative assay results and HIV subtype for all outliers identiﬁed for any of the four assays by pairwise Bland–Altman analysis.
Quantitative result (copies/ml)
Sample HIV subtype Aptima HIV RealTime Artus CAP/CTM Outlier identiﬁed comparing:
51 C 30 82 103 419 RealTime–Aptima
CAP/CTM–Aptima
RealTime–CAP/CTM
55 C 30 90 159 250 RealTime–Aptima
CAP/CTM–Aptima
67 Unknown 66 68 520 49 Artus–Aptima
CAP/CTM–Artus
201 B 71 50 207 28 CAP/CTM–Artus
80 A/B 154 427 <45 407 RealTime–Aptima
76 B 507 70 ND 189 RealTime–Aptima
45 B 3343 632 3610 5082 RealTime–Aptima
RealTime–Artus
RealTime–CAP/CTM
33 C 15,642 17,504 1715 18,200 Artus–Aptima
RealTime–Artus
CAP/CTM–Artus
21 D/A 74,718 50,530 13,417 101,000 RealTime–Artus
CAP/CTM–Artus
196 D/A 77,870 35,522 7178 36,600 Artus–Aptima
RealTime–Artus
CAP/CTM–Artus
11 CRF01 AE 469,706 151,604 57,470 246,000 Artus–Aptima
17 CRF02 AG 888,505 390,707 562,506 145,000 CAP/CTM–Aptima
204 B 6,508,605 5,143,319 929,000 3,460,000 Artus–Aptima
RealTime–Artus
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number. A weakness is the absence of follow-up data to establish
the clinical signiﬁcance of AptimaHIV results above 50 copies/ml. A
post-implementation clinical audit of low-level viraemia is planned
in order to address this.
To summarise, Aptima HIV has excellent comparative perfor-
mance across the metrics used in this study (accuracy, precision,
subtype detection, clinical sample testing) and provides a useful
new tool for monitoring HIV-1 RNA load in clinical laboratories.
Aptima HIV results for reliable RNA quantitation at low copy num-
ber appear promising, although studies with clinical follow-up are
required.
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